Could a common arthritis drug harm nerves? new study investigates.

NCT ID NCT06977035

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will use nerve conduction tests to check for nerve damage in 60 adults with rheumatoid arthritis. Half are taking baricitinib (Olumiant), a JAK inhibitor, and the other half are on standard disease-modifying drugs. The goal is to see if baricitinib is linked to a higher risk of peripheral neuropathy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

baricitinib

What this could lead to

If successful, this study could clarify whether baricitinib is linked to nerve damage in rheumatoid arthritis patients, helping guide safer treatment choices.

What could go wrong

This is a small, early observational study with only 60 participants. It cannot prove cause and effect, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sohag University Hospital

    RECRUITING

    Sohag, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••